Gynäkologisch-Onkologische Praxis Hannover
Industry / private company
Location:
Hannover,
Germany (DE)
ISNI: -
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole (2024)
Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al.
Journal article
A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial (2020)
Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching P, et al.
Journal article
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019)
Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P, et al.
Journal article
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice (2019)
Schneeweiss A, Denkert C, Fasching P, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ
Journal article
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial (2015)
Widschwendter P, Friedl TWP, Schwentner L, Degregorio N, Jaeger B, Schramm A, Bekes I, et al.
Journal article